Diaceutics PLC - 22% Revenue Growth H125 representing 3-yr CAGR 25%
Diaceutics PLC
("Diaceutics" or the "Company")
H1 2025 Trading Update
Revenue growth of 22% on a constant currency basis to £14.6 million in H1 2025 representing a 3-year CAGR of 25%
Continued strong commercial momentum in H1 2025
Order book of
Annual Recurring Revenue (ARR) up 16% to
17% growth in number of customer therapeutic brands Diaceutics is working with
New enterprise-wide agreement signed, bringing total to eight, representing
Diaceutics continues to demonstrate its ability to be the primary commercialisation partner for pharma and biotech companies launching precision medicines
Strong balance sheet with no debt and cash of
Ryan Keeling, Diaceutics' Chief Executive Officer, commented: "I am extremely pleased to report another period of strong operational and commercial execution, marked by double-digit organic revenue growth, expanding customer adoption and increased recurring revenue visibility. Despite macro-economic uncertainties globally, our customers remain active as they seek our help to improve patient access to therapy, capture lost revenue and increase profitability. Our continued growth demonstrates the significant value our customers place on our solutions, reflected by the increasing number of therapeutic brands we are working with. Our deepening engagement with enterprise clients, consistent growth in therapeutic brand count, and strong pipeline coverage into the historically stronger second half of the year, gives us confidence in delivering against both growth and profitability targets for the full year."
Trading Update to
Revenues grew 18% to
The Company continues to improve the sustainability and visibility of its revenues, with ARR growing 16% to
As at
Diaceutics secured a new multi-year enterprise-wide engagement with a total ARR of
DXRX platform adoption by pharma and biotech customers continues to drive business momentum with Diaceutics consistently working with 18 of the top 20 global pharma companies across 53 therapeutic brands in H1 2025. In H1 2025 to date, Diaceutics has worked with a total of 74 therapeutic brands across 43 customers (H1 2024: 44 customers and 63 therapeutic brands).
Diaceutics remains debt free and cash at
Outlook
|
· Global pharma and biotech customers are continuing to accelerate their shift to precision medicine to improve patient access, capture lost revenue and increase profitability |
|
· New enhanced technologies and product offerings across the platform are delivering continued operational leverage |
|
· Commercial pipeline and platform expansion expected to support continued margin improvement in H2 2025 |
|
· Future expansion of the market opportunities outside of precision medicine being explored |
|
· The Board reaffirms its confidence in the Company's strategy, operational performance and ability to continue delivering high-quality, recurring revenue growth and meeting FY 2025 growth and profitability targets |
All numbers stated are approximate and subject to audit.
*Analyst consensus estimates for FY 2025 revenue is
** EBITDA is earnings before interest, tax, depreciation and amortisation. Adjusted EBITDA removes share-based payment charges and once-off exceptional items.
Enquiries:
|
Diaceutics PLC |
|
|
|
Tel: +44 (0)28 9040 6500 investorrelations@diaceutics.com
|
|
|
|
|
Canaccord Genuity Limited (Nomad & Broker) |
Tel: +44 (0)20 7523 8000 |
|
|
|
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.
Prior to publication the information communicated in this announcement was deemed by the Company to constitute inside information for the purposes of article 7 of the Market Abuse Regulations (EU) No 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations No 2019/310 ('MAR'). With the publication of this announcement, this information is now considered to be in the public domain. The person responsible for making this announcement on behalf of the Company is
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE